Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of HRS-9231 in Renal Impairment
NCT06657560Phase 1Completed
- Start
- Oct 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HRS-9231 (5 arms). Primary endpoints: Maximum Plasma Concentration at Day 6, Area Under the Curve to Last Timepoint at Day 6 and 3 more. Started Oct 2024; status: completed.
02
Drugs
HRS-9231
Beyond the preview
Go deeper on NCT06657560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06657560.